245 related articles for article (PubMed ID: 12828295)
1. Effect of controlled-release oxybutynin on neurogenic bladder function in spinal cord injury.
O'Leary M; Erickson JR; Smith CP; McDermott C; Horton J; Chancellor MB
J Spinal Cord Med; 2003; 26(2):159-62. PubMed ID: 12828295
[TBL] [Abstract][Full Text] [Related]
2. Dosage escalation of intravesical oxybutynin in the treatment of neurogenic bladder patients.
Haferkamp A; Staehler G; Gerner HJ; Dörsam J
Spinal Cord; 2000 Apr; 38(4):250-4. PubMed ID: 10822396
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study.
Kennelly MJ; Lemack GE; Foote JE; Trop CS
Urology; 2009 Oct; 74(4):741-5. PubMed ID: 19628264
[TBL] [Abstract][Full Text] [Related]
4. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results.
Schurch B; Stöhrer M; Kramer G; Schmid DM; Gaul G; Hauri D
J Urol; 2000 Sep; 164(3 Pt 1):692-7. PubMed ID: 10953127
[TBL] [Abstract][Full Text] [Related]
5. Effect of intermittent urethral catheterization and oxybutynin bladder instillation on urinary continence status and quality of life in a selected group of spinal cord injury patients with neuropathic bladder dysfunction.
Vaidyananthan S; Soni BM; Brown E; Sett P; Krishnan KR; Bingley J; Markey S
Spinal Cord; 1998 Jun; 36(6):409-14. PubMed ID: 9648197
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of oxybutynin in children with detrusor hyperreflexia secondary to neurogenic bladder dysfunction.
Franco I; Horowitz M; Grady R; Adams RC; de Jong TP; Lindert K; Albrecht D
J Urol; 2005 Jan; 173(1):221-5. PubMed ID: 15592080
[TBL] [Abstract][Full Text] [Related]
7. Propiverine vs oxybutynin for treating neurogenic detrusor overactivity in children and adolescents: results of a multicentre observational cohort study.
Madersbacher H; Mürtz G; Alloussi S; Domurath B; Henne T; Körner I; Niedeggen A; Nounla J; Pannek J; Schulte-Baukloh H; Schultz-Lampel D; Bock P; Strugala G
BJU Int; 2009 Mar; 103(6):776-81. PubMed ID: 19007380
[TBL] [Abstract][Full Text] [Related]
8. Can higher doses of oxybutynin improve efficacy in neurogenic bladder?
Bennett N; O'Leary M; Patel AS; Xavier M; Erickson JR; Chancellor MB
J Urol; 2004 Feb; 171(2 Pt 1):749-51. PubMed ID: 14713802
[TBL] [Abstract][Full Text] [Related]
9. Intradetrusor onabotulinumtoxinA injections are significantly more efficacious than oral oxybutynin for treatment of neurogenic detrusor overactivity: results of a randomized, controlled, 24-week trial.
Ferreira RS; D'Ancona CAL; Oelke M; Carneiro MR
Einstein (Sao Paulo); 2018 Aug; 16(3):eAO4207. PubMed ID: 30088545
[TBL] [Abstract][Full Text] [Related]
10. Oxybutynin versus propantheline in patients with multiple sclerosis and detrusor hyperreflexia.
Gajewski JB; Awad SA
J Urol; 1986 May; 135(5):966-8. PubMed ID: 3959249
[TBL] [Abstract][Full Text] [Related]
11. Clinical reevaluation of the effect of oxybutynin chloride on uninhibited neurogenic and reflex neurogenic bladder.
Kawabe K; Abe S; Kanda T; Tei K
Urol Int; 1986; 41(1):16-20. PubMed ID: 3962017
[TBL] [Abstract][Full Text] [Related]
12. Intravesical instillation of oxybutynin hydrochloride therapy for patients with a neuropathic bladder.
Mizunaga M; Miyata M; Kaneko S; Yachiku S; Chiba K
Paraplegia; 1994 Jan; 32(1):25-9. PubMed ID: 8015832
[TBL] [Abstract][Full Text] [Related]
13. Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability.
Halaska M; Ralph G; Wiedemann A; Primus G; Ballering-Brühl B; Höfner K; Jonas U
World J Urol; 2003 May; 20(6):392-9. PubMed ID: 12811500
[TBL] [Abstract][Full Text] [Related]
14. The effectiveness of intravesical oxybutynin, propantheline, and capsaicin in the management of neuropathic bladder following spinal cord injury.
George J; Tharion G; Richar J; Macaden AS; Thomas R; Bhattacharji S
ScientificWorldJournal; 2007 Oct; 7():1683-90. PubMed ID: 17982563
[TBL] [Abstract][Full Text] [Related]
15. [Topical treatment with oxybutynin chloride in neurogenic incontinence].
López Pereira P; Martínez MJ; Muguerza R; Jaureguizar E
Cir Pediatr; 1993 Jan; 6(1):29-31. PubMed ID: 8499234
[TBL] [Abstract][Full Text] [Related]
16. A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence.
Madersbacher H; Halaska M; Voigt R; Alloussi S; Höfner K
BJU Int; 1999 Oct; 84(6):646-51. PubMed ID: 10510109
[TBL] [Abstract][Full Text] [Related]
17. Combined intravesical and oral oxybutynin chloride in adult patients with spinal cord injury.
Pannek J; Sommerfeld HJ; Bötel U; Senge T
Urology; 2000 Mar; 55(3):358-62. PubMed ID: 10699610
[TBL] [Abstract][Full Text] [Related]
18. Urodynamic changes associated with behavioral and drug treatment of urge incontinence in older women.
Goode PS; Burgio KL; Locher JL; Umlauf MG; Lloyd LK; Roth DL
J Am Geriatr Soc; 2002 May; 50(5):808-16. PubMed ID: 12028165
[TBL] [Abstract][Full Text] [Related]
19. Vardenafil improves urodynamic parameters in men with spinal cord injury: results from a single dose, pilot study.
Gacci M; Del Popolo G; Macchiarella A; Celso M; Vittori G; Lapini A; Serni S; Sandner P; Maggi M; Carini M
J Urol; 2007 Nov; 178(5):2040-3; discussion 2044. PubMed ID: 17869296
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of tolterodine in people with neurogenic detrusor overactivity.
Ethans KD; Nance PW; Bard RJ; Casey AR; Schryvers OI
J Spinal Cord Med; 2004; 27(3):214-8. PubMed ID: 15478523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
